Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Aug 12;58(8):1093.
doi: 10.3390/medicina58081093.

Pericardial Involvement in Severe COVID-19 Patients

Mihai Lazar  1   2 , Ecaterina Constanta Barbu  1 , Cristina Emilia Chitu  1 , Ana-Maria-Jennifer Anghel  2 , Cristian-Mihail Niculae  1   2 , Eliza-Daniela Manea  1   2 , Anca-Cristina Damalan  2 , Adela-Abigaela Bel  2 , Raluca-Elena Patrascu  1   2 , Adriana Hristea  1   2 , Daniela Adriana Ion  1
Affiliations
Observational Study

Pericardial Involvement in Severe COVID-19 Patients

Mihai Lazar et al. Medicina (Kaunas). .

Abstract

Background and Objectives: SARS-CoV-2 has an extensive tissue tropism due to its ability to attach to the surfaces of cells through different receptors, leading to systemic complications. In this article, we aim to present the prevalence of pericardial effusions in patients with severe COVID-19, to identify the risk factors/predictors for pericardial involvement, and to evaluate its impact on overall mortality. Materials and Methods: We enrolled 100 patients with severe COVID-19 in our observational cohort study and divided them in two groups: Group A (27 patients with pericardial effusion) and Group B (73 patients without pericardial effusion). We recorded demographic and lifestyle parameters, anthropometric parameters, clinical parameters, inflammation markers, respiratory function parameters, complete blood count, coagulation parameters, and biochemical serum parameters. All patients were evaluated by computer tomography scans within 48 h of admission. Results: The median age was 61 years in both groups and the male/female ratio was 3.5 vs. 2.8 in Group A vs. Group B. We identified mild pericardial effusion (3-4 mm) in 62.9% patients and moderate pericardial effusion (5-9 mm) in 37.1% patients, with a median value of 4 [3;6] mm. The patients with pericardial effusion presented with higher percentages of obesity, type-2 diabetes mellitus, arterial hypertension, and congestive heart failure, without statistical significance. Increased values in cardiac enzymes (myoglobin, CK, CK-MB) and LDH were statistically associated with pericardial effusion. The overall mortality among the participants of the study was 24% (24 patients), 33.3% in Group A and 20.8% in Group B. Conclusions: Pericardial effusion has a high prevalence (27%) among patients with severe forms of COVID-19 and was associated with higher mortality. Pericardial effusion in our study was not associated with the presence of comorbidities or the extent of lung involvement. Overall mortality was 60% higher in patients with pericardial effusion.

Keywords: COVID-19 complications; SARS-CoV-2; pericardial effusion; pericarditis; risk factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Pericardial effusion (white arrow) in a patient with a severe form of COVID-19 pneumonia.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zhang Q., Xiang R., Huo S., Zhou Y., Jiang S., Wang Q., Yu F. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduct. Target. Ther. 2021;6:233. doi: 10.1038/s41392-021-00653-w. - DOI - PMC - PubMed
    1. Buckley B.J., Harrison S.L., Fazio-Eynullayeva E., Underhill P., Lane D.A., Lip G.Y. Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients. Eur. J. Clin. Investig. 2021;51:e13679. doi: 10.1111/eci.13679. - DOI - PMC - PubMed
    1. National Institutes of Health (NIH) COVID-19 Treatment Guidelines, Clinical Spectrum of SARS-CoV-2 Infection. [(accessed on 4 June 2022)];2021 Available online: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/
    1. Anghel A.-M.-J., Niculae C.-M., Manea E.-D., Lazar M., Popescu M., Damalan A.-C., Bel A.-A., Nedelcu I.-M., Patrascu R.-E., Hristea A. The Impact of Tocilizumab on Radiological Changes Assessed by Quantitative Chest CT in Severe COVID-19 Patients. J. Clin. Med. 2022;11:1247. doi: 10.3390/jcm11051247. - DOI - PMC - PubMed
    1. Lazar M., Barbu E.C., Chitu C.E., Anghel A.-M.-J., Niculae C.-M., Manea E.-D., Damalan A.-C., Bel A.-A., Patrascu R.-E., Hristea A., et al. Mortality Predictors in Severe SARS-CoV-2 Infection. Medicina. 2022;58:945. doi: 10.3390/medicina58070945. - DOI - PMC - PubMed

Publication types